Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

Study acronym: ARC-10
StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 52 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Primary completion date changed from estimate of May 2027 to Sep 17, 2026
  2. Study sites: 39 to 38
    • Eligibility criteria expanded, about 13 words
  3. Trial sites reduced: 44 → 39 locationsv50
  4. Trial sites expanded: 39 → 44 locationsv49
  5. Site details revised at 1 of 39 sitesv48
  6. Re-verified, no change to tracked fieldsv47
  7. Trial sites reduced: 56 → 39 locationsv46
  8. Re-verified, no change to tracked fieldsv45
  9. Study sites: 92 to 56v44
  10. 2 versions Re-verified since Oct 15, 2025, no change to tracked fieldsv42-v43
  11. Study sites: 103 to 92v41
  12. Study sites: 104 to 103v40
  13. Study sites: 116 to 104v39
  14. Re-verified, no change to tracked fieldsv38
  15. Study sites: 115 to 116v37
  16. Study sites: 167 to 115v36
  17. Phase: Phase 3 to Phase 2v35 Show 6 more changesShow less
    • Primary completion date: Aug 31, 2024 to May 2027
    • Primary endpoint revised
    • Study completion date: Jul 1, 2027 to May 2027
    • Secondary endpoints: 4 to 3
    • Study title shortened, about 8 words
    • Eligibility criteria expanded, about 3 words
  18. Study sites: 170 to 167v34
  19. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 750 to confirmed 169
    • Study sites: 171 to 170
    v33
  20. Site details revised at 1 of 171 sitesv32
  21. Study sites: 165 to 171v31
  22. Study sites: 156 to 165v30
  23. Study sites: 154 to 156v29
  24. Study sites: 150 to 154v28
  25. Study sites: 149 to 150v27
  26. Site details revised at 6 of 149 sitesv26
  27. Study sites: 147 to 149v25
  28. Site details revised at 2 of 147 sitesv24
  29. Site details revised at 5 of 147 sitesv23
  30. Study sites: 141 to 147v22
  31. Study sites: 140 to 141v21
  32. Primary completion date: Dec 31, 2025 to Aug 31, 2024v20 Show 7 more changesShow less
    • Primary endpoints: 3 to 1
    • Enrollment target: 625 to 750
    • Study completion date: Jun 30, 2026 to Jul 1, 2027
    • Interventions: Carboplatin (Drug), Domvanalimab (Drug), Paclitaxel (Drug), Pemetrexed (Drug), Zimberelimab (Drug) to Carboplatin (Drug), Domvanalimab (Drug), Paclitaxel (Drug), Pembrolizumab (Drug), Pemetrexed (Drug), Zimberelimab (Drug)
    • Secondary endpoints: 7 to 4
    • Site details revised at 1 of 140 sites
    • Study arms: 3 to 5
  33. Study sites revised (140)v19
  34. Study sites: 183 to 140v18
  35. Study sites revised (183)v17
  36. Start date: Feb 1, 2021 to Feb 8, 2021v16
  37. Study Status, Sponsor/Collaboratorsv15
  38. Study sites revised (183)v14
  39. Study sites: 184 to 183v13
  40. Study sites: 183 to 184v12
  41. Study sites: 202 to 183v11
  42. Study sites revised (202)v10
  43. Study sites: 200 to 202v9
  44. Study sites: 201 to 200v8
  45. Study sites revised (201)v7
  46. Study sites: 4 to 201
    • Secondary endpoints revised (7)
    v6
  47. Secondary endpoints: 3 to 7
    • Primary endpoints revised (3)
    v5
  48. Primary endpoints: 1 to 3
    • Interventions: AB154 (Drug), Carboplatin (Drug), Paclitaxel (Drug), Pemetrexed (Drug), Zimberelimab (Drug) to Carboplatin (Drug), Domvanalimab (Drug), Paclitaxel (Drug), Pemetrexed (Drug), Zimberelimab (Drug)
    • Secondary endpoints: 2 to 3
    v4
  49. Study sites: 5 to 4v3
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
Trial Details
NCT Number NCT04736173
Lead Sponsor Arcus Biosciences, Inc.
Collaborators: Gilead Sciences
Conditions
(from sponsor)		 Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Enrollment 169 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov